Cindy Tahl Net Worth

The estimated Net Worth of Cindy Tahl is at least $5.54 million dollars as of 9 January 2024. Ms. Tahl owns over 10,874 units of Fate Therapeutics Inc stock worth over $552,361 and over the last 9 years she sold FATE stock worth over $2,173,266. In addition, she makes $2,818,590 as General Counsel and Corporate Secretary at Fate Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Tahl FATE stock SEC Form 4 insiders trading

Cindy has made over 22 trades of the Fate Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 10,874 units of FATE stock worth $47,519 on 9 January 2024.

The largest trade she's ever made was exercising 70,801 units of Fate Therapeutics Inc stock on 4 November 2020 worth over $194,703. On average, Cindy trades about 16,881 units every 67 days since 2015. As of 9 January 2024 she still owns at least 142,361 units of Fate Therapeutics Inc stock.

You can see the complete history of Ms. Tahl stock trades at the bottom of the page.

Cindy Tahl biography

Cindy R. Tahl J.D. is the General Counsel and Corporate Secretary of Fate Therapeutics Inc. She previously served as our Vice President, IP and Senior Corporate Counsel from December 2013 to October 2015. From 2009 to 2013, Ms. Tahl served as our Senior Director, Intellectual Property and Corporate Counsel. From 2007 to 2009, Ms. Tahl was a technology transactions attorney at the law firm of Wilson Sonsini Goodrich and Rosati, P.C, and from 2004 to 2007 practiced intellectual property law in the New York office of Kenyon & Kenyon, LLP. Ms. Tahl received her J.D. from Boston College Law School and her B.S. in biology from the University of California, San Diego.

What is the salary of Cindy Tahl?

As the General Counsel and Corporate Secretary of Fate Therapeutics Inc, the total compensation of Cindy Tahl at Fate Therapeutics Inc is $2,818,590. There are 1 executives at Fate Therapeutics Inc getting paid more, with John Wolchko having the highest compensation of $10,721,000.

How old is Cindy Tahl?

Cindy Tahl is 47, she's been the General Counsel and Corporate Secretary of Fate Therapeutics Inc since 2015. There are 10 older and 6 younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.

What's Cindy Tahl's mailing address?

Cindy's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131.

Insiders trading at Fate Therapeutics Inc

Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part... et Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.

What does Fate Therapeutics Inc do?

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Complete history of Ms. Tahl stock trades at Fate Therapeutics Inc

Fate Therapeutics Inc executives and stock owners

Fate Therapeutics Inc executives and other stock owners filed with the SEC include:

• John Wolchko,
  President, Chief Executive Officer, Director
• Bahram Valamehr,
  Chief Development Officer
• Cindy Tahl,
  General Counsel and Corporate Secretary
• Daniel Shoemaker,
  Chief Scientific Officer
• J. Scott Wolchko,
  Founder, CEO, Pres & Director
• Dr. Bahram Valamehr Ph.D.,
  Chief R&D Officer
• Cindy R. Tahl,
  Gen. Counsel & Corp. Sec.
• Karin Jooss,
  Independent Director
• Shefali Agarwal,
  Director
• William Rastetter,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• John Mendlein,
  Independent Vice Chairman of the Board
• Robert Epstein,
  Independent Director
• Michael Lee,
  Independent Director
• Edward Dulac,
  Chief Financial Officer
• Robert Hershberg,
  Director
• Renee Leck,
  IR Contact Officer
• Yu-Waye Chu,
  Vice President - Clinical Development
• Sarah Cooley,
  Senior Vice President - Clinical Translation
• Dr. Mark Plavsic D.V.M., Ph.D.,
  Chief Technical Officer
• Dr. Yu-Waye Chu M.D.,
  Sr. VP of Clinical Devel.
• Jim Beitel M.B.A.,
  Sr. VP of Corp. Devel.
• Dr. Wen Bo Wang,
  Sr. VP of Technical Operations
• Edward J. Dulac III,
  CFO & Principal Accounting Officer
• Mark J Enyedy,
  Director
• Stewart Abbot,
  Chief Development Officer
• Chris Storgard,
  Chief Medical Officer
• Amir Nashat,
  Director
• Brian T. Powl,
  Chief Commercial Officer
• J Scott Wolchko,
  President and CEO
• Group, Llc Green Jeremy Red...,
  
• Pratik S Multani,
  Chief Medical Officer
• Peter D Flynn,
  See remarks
• Christian Weyer,
  See remarks
• Venture Fund Vi Lparch Vent...,
  
• Venture Partners Vii Lpovp ...,
  
• Venture Management Co. V, L...,
  
• Robert Nelsen,
  Director
• Associates V Lpvenrock Part...,
  
• Yuan Xu,
  
• Mark Plavsic,
  Chief Technical Officer
• Neelufar Mozaffarian,